Review



108 pfu oav  (Vector Laboratories)


Bioz Verified Symbol Vector Laboratories is a verified supplier
Bioz Manufacturer Symbol Vector Laboratories manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Vector Laboratories 108 pfu oav
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    108 Pfu Oav, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 122 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pmc12722228-91-57-60?v=Vector+Laboratories
    Average 93 stars, based on 122 article reviews
    108 pfu oav - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis"

    Article Title: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

    Journal: Signal Transduction and Targeted Therapy

    doi: 10.1038/s41392-025-02511-5

    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu OAV were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Figure Legend Snippet: Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu OAV were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant

    Techniques Used: Expressing, Infection, Plasmid Preparation, Saline, Injection, Immunofluorescence

    Construction and in vivo validation of NeoViron. a ‒ d C57BL/6 mice inoculated with mICCN-4 or Hep53.4 cells were treated with PBS, vector or AdSVP-Flt3L. For the mICCN-4 model, treatment was initiated on day 8, with intratumoral injections of 1 × 10⁸ pfu OAV administered every other day for a total of five doses. For Hep53.4 tumors, treatment commenced on Day 6 with intratumoral injections of 2 × 10⁸ pfu OAV every other day for five doses. a , b Left, tumor images at the end point. Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 10⁸ pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). g Percentages of PD1+ GZMB+ CD8+ T cells and PD1+ GZMB- CD8+ T cells infiltrating the tumor tissues of each group. h Representative immunofluorescence images of GZMB+ CD8+ T cells in tumor tissues. The data are shown as the means ± SDs ( a – g ) and are representative of two ( a – h ) independent experiments. Significance was calculated via one-way ANOVA ( a – c , g ) or two-way ANOVA ( a , b , f ). * P < 0.05, ** P < 0.01, *** P < 0.001. ns not significant
    Figure Legend Snippet: Construction and in vivo validation of NeoViron. a ‒ d C57BL/6 mice inoculated with mICCN-4 or Hep53.4 cells were treated with PBS, vector or AdSVP-Flt3L. For the mICCN-4 model, treatment was initiated on day 8, with intratumoral injections of 1 × 10⁸ pfu OAV administered every other day for a total of five doses. For Hep53.4 tumors, treatment commenced on Day 6 with intratumoral injections of 2 × 10⁸ pfu OAV every other day for five doses. a , b Left, tumor images at the end point. Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 10⁸ pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). g Percentages of PD1+ GZMB+ CD8+ T cells and PD1+ GZMB- CD8+ T cells infiltrating the tumor tissues of each group. h Representative immunofluorescence images of GZMB+ CD8+ T cells in tumor tissues. The data are shown as the means ± SDs ( a – g ) and are representative of two ( a – h ) independent experiments. Significance was calculated via one-way ANOVA ( a – c , g ) or two-way ANOVA ( a , b , f ). * P < 0.05, ** P < 0.01, *** P < 0.001. ns not significant

    Techniques Used: In Vivo, Biomarker Discovery, Plasmid Preparation, Flow Cytometry, Immunofluorescence, Staining, Immunopeptidomics



    Similar Products

    108 pfu oav  (Vector Laboratories)
    93
    Vector Laboratories 108 pfu oav
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    108 Pfu Oav, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pmc12722228-91-57-60?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    108 pfu oav - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    ln βg cbh ∕ ln nag lap ue  (Vector Laboratories)
    93
    Vector Laboratories ln βg cbh ∕ ln nag lap ue
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Ln βg Cbh ∕ Ln Nag Lap Ue, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pm41317400-274-17-25?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    ln βg cbh ∕ ln nag lap ue - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    ∕ ln nag lap 2 ln bg cbh ∕ ln ap  (Vector Laboratories)
    93
    Vector Laboratories ∕ ln nag lap 2 ln bg cbh ∕ ln ap
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    ∕ Ln Nag Lap 2 Ln Bg Cbh ∕ Ln Ap, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/10__1111_slash_1365___2664__70215-94-61-63?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    ∕ ln nag lap 2 ln bg cbh ∕ ln ap - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    ln bg ln ap 2  (Vector Laboratories)
    93
    Vector Laboratories ln bg ln ap 2
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Ln Bg Ln Ap 2, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pm41004966-112-12-24?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    ln bg ln ap 2 - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    ln nag lap 2 eesc  (Vector Laboratories)
    93
    Vector Laboratories ln nag lap 2 eesc
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Ln Nag Lap 2 Eesc, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/10__1111_slash_1365___2435__70100-113-17-38?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    ln nag lap 2 eesc - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    erythrina crista galli lectin  (Vector Laboratories)
    93
    Vector Laboratories erythrina crista galli lectin
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Erythrina Crista Galli Lectin, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pm40472900-58-22-48?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    erythrina crista galli lectin - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    nag 1 expression vector  (Vector Laboratories)
    93
    Vector Laboratories nag 1 expression vector
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Nag 1 Expression Vector, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pm40399974-167-4-6?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    nag 1 expression vector - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    √ ln bg ln  (Vector Laboratories)
    93
    Vector Laboratories √ ln bg ln
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    √ Ln Bg Ln, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pm40431239-131-14-25?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    √ ln bg ln - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    glcnac  (Vector Laboratories)
    93
    Vector Laboratories glcnac
    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu <t>OAV</t> were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant
    Glcnac, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/S-9002/pmc11980833-219-12-13?v=Vector+Laboratories
    Average 93 stars, based on 1 article reviews
    glcnac - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu OAV were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

    doi: 10.1038/s41392-025-02511-5

    Figure Lengend Snippet: Efficacy of AdSVP-NAgmICC in ICCs with few mutations. a Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of C57BL/6 mice inoculated with mICCN-4. b Relative expression of neoantigen (NAg) in mICCN-4 cells infected with AdSVP-NAg mICC at 0 h, 48 h, and 96 h determined by qRT‒PCR. c Mass spectra of epitopes in mICCN-4 cells detected by LC‒MS/MS following infection with AdSVP-NAg mICC for 96 h. d ‒ g C57BL/6 mice inoculated with mICCN-4 were treated with PBS, vector, SLP, vector combined with SLP, or AdSVP-NAg mICC . d Left, experimental schematic. On Day 0, 1 × 10⁶ tumor cells were resuspended in 100 μL of saline and subcutaneously injected into the mice. Intratumoral injections of PBS or 2 × 10⁸ pfu OAV were administered every other day starting from Day 8, while subcutaneous injections of SLP were initiated on Day 7 and continued every other day for a total of five doses. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). e Representative images of IFN-γ ELISpots of neoantigen-specific T cells from the spleens of each group. f , g Representative immunofluorescence images of tumor tissues. The data are shown as the means ± SDs ( d ) and are representative of two independent experiments ( a – g ). Significance was calculated by two-way ANOVA ( c ). ** P < 0.01, *** P < 0.001. ns not significant

    Article Snippet: Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 108 pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic.

    Techniques: Expressing, Infection, Plasmid Preparation, Saline, Injection, Immunofluorescence

    Construction and in vivo validation of NeoViron. a ‒ d C57BL/6 mice inoculated with mICCN-4 or Hep53.4 cells were treated with PBS, vector or AdSVP-Flt3L. For the mICCN-4 model, treatment was initiated on day 8, with intratumoral injections of 1 × 10⁸ pfu OAV administered every other day for a total of five doses. For Hep53.4 tumors, treatment commenced on Day 6 with intratumoral injections of 2 × 10⁸ pfu OAV every other day for five doses. a , b Left, tumor images at the end point. Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 10⁸ pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). g Percentages of PD1+ GZMB+ CD8+ T cells and PD1+ GZMB- CD8+ T cells infiltrating the tumor tissues of each group. h Representative immunofluorescence images of GZMB+ CD8+ T cells in tumor tissues. The data are shown as the means ± SDs ( a – g ) and are representative of two ( a – h ) independent experiments. Significance was calculated via one-way ANOVA ( a – c , g ) or two-way ANOVA ( a , b , f ). * P < 0.05, ** P < 0.01, *** P < 0.001. ns not significant

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

    doi: 10.1038/s41392-025-02511-5

    Figure Lengend Snippet: Construction and in vivo validation of NeoViron. a ‒ d C57BL/6 mice inoculated with mICCN-4 or Hep53.4 cells were treated with PBS, vector or AdSVP-Flt3L. For the mICCN-4 model, treatment was initiated on day 8, with intratumoral injections of 1 × 10⁸ pfu OAV administered every other day for a total of five doses. For Hep53.4 tumors, treatment commenced on Day 6 with intratumoral injections of 2 × 10⁸ pfu OAV every other day for five doses. a , b Left, tumor images at the end point. Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 10⁸ pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). g Percentages of PD1+ GZMB+ CD8+ T cells and PD1+ GZMB- CD8+ T cells infiltrating the tumor tissues of each group. h Representative immunofluorescence images of GZMB+ CD8+ T cells in tumor tissues. The data are shown as the means ± SDs ( a – g ) and are representative of two ( a – h ) independent experiments. Significance was calculated via one-way ANOVA ( a – c , g ) or two-way ANOVA ( a , b , f ). * P < 0.05, ** P < 0.01, *** P < 0.001. ns not significant

    Article Snippet: Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 108 pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic.

    Techniques: In Vivo, Biomarker Discovery, Plasmid Preparation, Flow Cytometry, Immunofluorescence, Staining, Immunopeptidomics